Genolution's earnings have been declining at an average annual rate of -66.5%, while the Life Sciences industry saw earnings declining at 3.1% annually. Revenues have been growing at an average rate of 23.7% per year.
How Genolution makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
KOSDAQ:A225220 Revenue, expenses and earnings (KRW Millions)
Date
Revenue
Earnings
G+A Expenses
R&D Expenses
31 Mar 26
9,821
-8,968
8,885
445
31 Dec 25
9,404
-11,643
9,481
472
30 Sep 25
9,146
-8,059
9,968
609
30 Jun 25
8,767
-10,257
9,603
933
31 Mar 25
7,942
-8,939
8,666
1,513
31 Dec 24
7,136
-6,826
8,074
1,672
30 Sep 24
7,283
-9,442
7,621
2,347
30 Jun 24
7,662
-6,716
7,216
2,550
31 Mar 24
7,914
-6,079
7,194
3,179
31 Dec 23
9,761
-5,512
7,076
3,081
31 Dec 22
38,085
14,602
8,784
1,516
Quality Earnings: A225220 is currently unprofitable.
Growing Profit Margin: A225220 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: A225220 is unprofitable, and losses have increased over the past 5 years at a rate of 66.5% per year.
Accelerating Growth: Unable to compare A225220's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: A225220 is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (-26.7%).
Return on Equity
High ROE: A225220 has a negative Return on Equity (-14.48%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
7D
1Y
7D
1Y
7D
1Y
Company Analysis and Financial Data Status
Data
Last Updated (UTC time)
Company Analysis
2026/07/04 14:06
End of Day Share Price
2026/07/03 00:00
Earnings
2026/03/31
Annual Earnings
2025/12/31
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Genolution Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.